In this fifth episode of our recently launched CXO Talks, we spoke with a distinguished panel of speakers from Auxilius Pharma, Jed Litwiniuk, the CEO, and Uwe Tigör, the CMO of the company. Auxilius Pharma is an emerging specialized pharma company aimed at developing, optimizing, and delivering well-established medications internationally.
Jed & Uwe walked memory lane on how the company came to exit and highlighted the challenges and opportunities waiting in the wonderful journey. Reminiscing our old conversation on Auxilius’ lead candidate AUX-001, the duo shed light on their recent presentation at the European Society of Cardiology (ESC 2024), where the company presented results from Phase 1a.
Jed and Uwe took PharmaShots on a vicarious excursion of Auxilius’ pipeline, highlighting AUX-002 and AUX-003 currently in formulation.
Image Source: Canva
About the Author:
Jed Litwiniuk
Pharmaceutical and Healthcare Executive and Corporate Finance Professional with over 15 years of experience on both sides of the Atlantic. Before co-founding Auxilius Pharma Jed worked for a range of institutions investing in the healthcare space. His experience includes roles such as head of M&A of Lux Med (the largest healthcare provider in CEE), Investment Director at Enterprise Venture Fund and PZU (the largest CEE insurance group). CEO of orthopedics and spine surgery inpatient clinic (CM Gamma). Co-founder of Picket Pharmaceuticals, NYC based start-up. In 2019 Jed gained Executive Master of Health Administration degree at Columbia University Mailman School of Public Health and focused his work on developing Auxilius Pharma.
Uwe Tigör
Extensive marketing and product launch experience as Chief Medical Officer and Medical Director in healthcare marketing and communications agencies from IPG, WPP, HAVAS Health to InventivHealth; consultant to Pharmaceutical Industry. Medical training in EU and US, MD from Humboldt University, Berlin. Cardiovascular research experience including a research fellowship at Mount Sinai Hospital, NY. MHA candidate at Columbia University Mailman School of Public Health
Related Post: CXO Talks: Rashmi Gurnani from AKT Health Analytics in a Riveting Dialogue Exchange with PharmaShots
